Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival. Immunotherapies directed against cancer cell-surface antigens, such as chimeric antigen receptor (CAR) T-cell therapy and T-cell-redirecting bispecific antibodies, have recently received regulatory approvals and shown unprecedented efficacy. However, these immunotherapies have unique mechanisms of action and toxicities that are different to previous treatments for myeloma, so experiences from clinical trials and early access programmes are essential for providing specific recommendations for management of patients, especially as these agents become available across many parts of the world. Here, we provide expert consensus clinical practice guidelines for the use of bispecific antibodies for the treatment of myeloma. The International Myeloma Working Group is also involved in the collection of prospective real-time data of patients treated with such immunotherapies, with the aim of learning continuously and adapting clinical practices to optimise the management of patients receiving immunotherapies.
- MeSH
- imunoterapie metody normy MeSH
- konsensus * MeSH
- lidé MeSH
- mnohočetný myelom * imunologie terapie farmakoterapie MeSH
- protilátky bispecifické * terapeutické užití MeSH
- protinádorové látky imunologicky aktivní terapeutické užití škodlivé účinky MeSH
- T-lymfocyty * imunologie účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- směrnice pro lékařskou praxi MeSH
Monitoring is a major component of asthma management in children. Regular monitoring allows for diagnosis confirmation, treatment optimization, and natural history review. Numerous factors that may affect disease activity and patient well-being need to be monitored: response and adherence to treatment, disease control, disease progression, comorbidities, quality of life, medication side-effects, allergen and irritant exposures, diet and more. However, the prioritization of such factors and the selection of relevant assessment tools is an unmet need. Furthermore, rapidly developing technologies promise new opportunities for closer, or even "real-time," monitoring between visits. Following an approach that included needs assessment, evidence appraisal, and Delphi consensus, the PeARL Think Tank, in collaboration with major international professional and patient organizations, has developed a set of 24 recommendations on pediatric asthma monitoring, to support healthcare professionals in decision-making and care pathway design.
- MeSH
- antiastmatika terapeutické užití MeSH
- bronchiální astma * diagnóza terapie MeSH
- delfská metoda MeSH
- dítě MeSH
- kvalita života MeSH
- lidé MeSH
- monitorování fyziologických funkcí metody MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- směrnice pro lékařskou praxi MeSH
- MeSH
- analgosedace MeSH
- antibiotická profylaxe MeSH
- gastrointestinální endoskopie klasifikace metody normy MeSH
- gastrointestinální krvácení diagnóza prevence a kontrola terapie MeSH
- gastrointestinální nemoci diagnóza prevence a kontrola terapie MeSH
- hematologické látky aplikace a dávkování MeSH
- hemostáza endoskopická metody MeSH
- kolonoskopie * klasifikace metody normy škodlivé účinky MeSH
- lidé MeSH
- předoperační péče metody MeSH
- riziko MeSH
- roztoky analýza klasifikace terapeutické užití MeSH
- terciární prevence metody MeSH
- vysazování léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- směrnice pro lékařskou praxi MeSH
- Klíčová slova
- vývojová dysfázie,
- MeSH
- afázie diagnóza etiologie klasifikace MeSH
- diferenciální diagnóza MeSH
- dítě MeSH
- lidé MeSH
- management nemoci MeSH
- nemoci jazyka * klasifikace terapie vrozené MeSH
- neurovývojové poruchy * diagnóza klasifikace MeSH
- poruchy řeči diagnóza klasifikace MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- směrnice pro lékařskou praxi MeSH
- MeSH
- lidé MeSH
- meningokokové infekce * epidemiologie prevence a kontrola MeSH
- očkovací schéma MeSH
- sekundární imunizace MeSH
- vakcinace * normy MeSH
- věkové faktory MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- směrnice pro lékařskou praxi MeSH
- MeSH
- antibakteriální látky * aplikace a dávkování terapeutické užití MeSH
- antibiotická profylaxe MeSH
- bakteriální infekce prevence a kontrola MeSH
- lidé MeSH
- perioperační péče metody MeSH
- pooperační komplikace prevence a kontrola MeSH
- rizikové faktory MeSH
- rozvrh dávkování léků MeSH
- stomatochirurgické výkony ošetřování MeSH
- stomatologické nemoci * farmakoterapie MeSH
- úrazy zubů farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- směrnice pro lékařskou praxi MeSH
INTRODUCTION: Hip and knee osteoarthritis (OA) are increasingly common with a significant impact on individuals and society. Non-pharmacological treatments are considered essential to reduce pain and improve function and quality of life. EULAR recommendations for the non-pharmacological core management of hip and knee OA were published in 2013. Given the large number of subsequent studies, an update is needed. METHODS: The Standardised Operating Procedures for EULAR recommendations were followed. A multidisciplinary Task Force with 25 members representing 14 European countries was established. The Task Force agreed on an updated search strategy of 11 research questions. The systematic literature review encompassed dates from 1 January 2012 to 27 May 2022. Retrieved evidence was discussed, updated recommendations were formulated, and research and educational agendas were developed. RESULTS: The revised recommendations include two overarching principles and eight evidence-based recommendations including (1) an individualised, multicomponent management plan; (2) information, education and self-management; (3) exercise with adequate tailoring of dosage and progression; (4) mode of exercise delivery; (5) maintenance of healthy weight and weight loss; (6) footwear, walking aids and assistive devices; (7) work-related advice and (8) behaviour change techniques to improve lifestyle. The mean level of agreement on the recommendations ranged between 9.2 and 9.8 (0-10 scale, 10=total agreement). The research agenda highlighted areas related to these interventions including adherence, uptake and impact on work. CONCLUSIONS: The 2023 updated recommendations were formulated based on research evidence and expert opinion to guide the optimal management of hip and knee OA.
- MeSH
- artróza kolenních kloubů * terapie rehabilitace MeSH
- artróza kyčelních kloubů * terapie rehabilitace MeSH
- hmotnostní úbytek MeSH
- lidé MeSH
- medicína založená na důkazech MeSH
- pomůcky pro sebeobsluhu MeSH
- self-management metody MeSH
- terapie cvičením * metody MeSH
- vzdělávání pacientů jako téma metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
- Geografické názvy
- Evropa MeSH
Experts from the European Leukemia Net (ELN) working group for adult acute lymphoblastic leukemia have identified an unmet need for guidance regarding management of adult acute lymphoblastic leukemia (ALL) from diagnosis to aftercare. The group has previously summarized their recommendations regarding diagnostic approaches, prognostic factors, and assessment of ALL. The current recommendation summarizes clinical management. It covers treatment approaches, including the use of new immunotherapies, application of minimal residual disease for treatment decisions, management of specific subgroups, and challenging treatment situations as well as late effects and supportive care. The recommendation provides guidance for physicians caring for adult patients with ALL which has to be complemented by regional expertise preferably provided by national academic study groups.
- MeSH
- akutní lymfatická leukemie * terapie diagnóza MeSH
- dospělí MeSH
- lidé MeSH
- management nemoci MeSH
- prognóza MeSH
- reziduální nádor diagnóza terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- směrnice pro lékařskou praxi MeSH
- Geografické názvy
- Evropa MeSH
Working groups of the European LeukemiaNet have published several important consensus guidelines. Acute lymphoblastic leukemia (ALL) has many different clinical and biological subgroups and the knowledge on disease biology and therapeutic options is increasing exponentially. The European Working Group for Adult ALL has therefore summarized the current state of the art and provided comprehensive consensus recommendations for diagnostic approaches, biologic and clinical characterization, prognostic factors, and risk stratification as well as definitions of endpoints and outcomes. Aspects of treatment, management of subgroups and specific situations, aftercare, and supportive care are covered in a separate publication. The present recommendation intends to provide guidance for the initial management of adult patients with ALL and to define principles as a basis for future collaborative research.